Japan Regenerative Medicine Market 2016-2020: High Cost and Failure Rate in Clinical Trials Coupled with Inadequate Clinical Evidence Presents Market Challenges - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Regenerative Medicine Market in Japan 2016-2020" report to their offering.

The regenerative medicine market in Japan to grow at a CAGR of 35.3% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the regenerative medicine market in Japan for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various types of regenerative medicine products to end-users like hospitals, ambulatory surgical centers (ASCs), and clinical research laboratories. The report also includes a discussion of the key vendors operating in this market.

Regenerative medicine deals with the process of using therapeutically induced or laboratory-grown human tissue to treat damaged or diseased human cells, tissues, or organs. It focuses on repairing, replacing, or regenerating damaged cells, and thus offers a paradigm shift in healthcare treatment. The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy. Small molecules and biologics help in the regeneration of diseased cells and tissues, whereas cell therapy helps in treating the functioning of existing cells.

Key vendors

  • CellSeed
  • JCR Pharmaceuticals
  • Japan Tissue Engineering
  • Terumo
  • Astellas
  • Caladrius Biosciences
  • Healios
  • Fujifilm
  • Rohto Pharmaceuticals

Other prominent vendors

  • FUJISOFT Tissue Engineering
  • MediBIC
  • MEDI NET
  • Nikon
  • TAKARA
  • CMIC
  • EPS
  • Cyfuse Biomedical
  • Irvine Scientific
  • Kaken
  • Regience
  • Sumitomo Dainippon
  • Takeda
  • Alfresa
  • MEDIPAL Holdings
  • TOHO

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Healthcare reforms in Japan

Part 06: Regulatory landscape in Japan

Part 07: Reimbursement scenario

Part 08: Gene therapy: An emerging field in regenerative medicine

Part 09: Pipeline portfolio

Part 10: Market landscape

Part 11: Market segmentation by product

Part 12: Market segmentation by application

Part 13: Market drivers

Part 14: Impact of drivers

Part 15: Market challenges

Part 16: Impact of drivers and challenges

Part 17: Market trends

Part 18: Vendor landscape

Part 19: Key vendor analysis

Part 20: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/ct9sp9/regenerative

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biopharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biopharmaceuticals